More on EPRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.59 |
|
|||
| Open | $7.51 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $7.61 | ||||
| Day Low | $6.70 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 348,797 | ||||
- Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 22
- Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
- H.C. Wainwright Reiterates Buy Rating on Eupraxia Pharmaceuticals (EPRX)
- Oppenheimer Reiterates Outperform Rating on Eupraxia Pharmaceuticals (EPRX)
- Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 15
- Eupraxia hits enrollment target in EoE drug trial, interim data due
- Eupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic Esophagitis
- Form 6-K EUPRAXIA PHARMACEUTICALS For: Oct 09
- Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
- Eupraxia Pharmaceuticals (EPRX) Reiterated at Overweight by Cantor Fitzgerald - 'Stock Remains Undervalued'
Entities mentioned with EPRX
- FDA | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Cantor Fitzgerald | View Related Stories »
- Earnings | View Related Stories »
- Raymond James | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Show More...
